Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4′-methanol- bisbenzonitrile in vitro

Seongwook Jeong, Margaret M. Woo, David A. Flockhart, Zeruesenay Desta

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Purpose: To determine the inhibitory potency of letrozole and its main human metabolite, 4,4′-methanol-bisbenzonitrile, on the activities of eight cytochrome P450 (CYP) enzymes. Methods: Letrozole and its metabolite were incubated with human liver microsomes (HLMs) (or expressed CYP isoforms) and NADPH in the absence (control) and presence of the test inhibitor. Results: Letrozole was a potent competitive inhibitor of CYP2A6 (Ki 4.6 ± 0.05 μM and 5.0 ± 2.4 μM in HLMs and CYP2A6, respectively) and a weak inhibitor of CYP2C19 (Ki 42.2 μM in HLMs and 33.3 μM in CYP2C19), while its metabolite showed moderate inhibition of CYP2C19 and CYP2B6. Letrozole or its metabolite had negligible effect on other CYPs. Conclusions: Based on the in vitro Ki values, letrozole is predicted to be a weak inhibitor of CYP2A6 in vivo. Letrozole and its major human metabolite show inhibitory activity towards other CYPs, but clinically relevant drug interactions seem less likely as the Ki values are above the therapeutic plasma concentrations of letrozole.

Original languageEnglish
Pages (from-to)867-875
Number of pages9
JournalCancer Chemotherapy and Pharmacology
Volume64
Issue number5
DOIs
StatePublished - Oct 2009

Fingerprint

letrozole
Aromatase Inhibitors
Cytochromes
Metabolites
Methanol
Pharmaceutical Preparations
Liver Microsomes
Liver
Cytochrome P-450 Enzyme System
Drug interactions
In Vitro Techniques
NADP
Drug Interactions

Keywords

  • Aromatase inhibitor
  • Cytochrome P450
  • Drug interaction
  • Letrozole
  • Metabolite

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Toxicology

Cite this

Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4′-methanol- bisbenzonitrile in vitro. / Jeong, Seongwook; Woo, Margaret M.; Flockhart, David A.; Desta, Zeruesenay.

In: Cancer Chemotherapy and Pharmacology, Vol. 64, No. 5, 10.2009, p. 867-875.

Research output: Contribution to journalArticle

@article{e0b40694893d413f84202347b112c57b,
title = "Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4′-methanol- bisbenzonitrile in vitro",
abstract = "Purpose: To determine the inhibitory potency of letrozole and its main human metabolite, 4,4′-methanol-bisbenzonitrile, on the activities of eight cytochrome P450 (CYP) enzymes. Methods: Letrozole and its metabolite were incubated with human liver microsomes (HLMs) (or expressed CYP isoforms) and NADPH in the absence (control) and presence of the test inhibitor. Results: Letrozole was a potent competitive inhibitor of CYP2A6 (Ki 4.6 ± 0.05 μM and 5.0 ± 2.4 μM in HLMs and CYP2A6, respectively) and a weak inhibitor of CYP2C19 (Ki 42.2 μM in HLMs and 33.3 μM in CYP2C19), while its metabolite showed moderate inhibition of CYP2C19 and CYP2B6. Letrozole or its metabolite had negligible effect on other CYPs. Conclusions: Based on the in vitro Ki values, letrozole is predicted to be a weak inhibitor of CYP2A6 in vivo. Letrozole and its major human metabolite show inhibitory activity towards other CYPs, but clinically relevant drug interactions seem less likely as the Ki values are above the therapeutic plasma concentrations of letrozole.",
keywords = "Aromatase inhibitor, Cytochrome P450, Drug interaction, Letrozole, Metabolite",
author = "Seongwook Jeong and Woo, {Margaret M.} and Flockhart, {David A.} and Zeruesenay Desta",
year = "2009",
month = "10",
doi = "10.1007/s00280-009-0935-7",
language = "English",
volume = "64",
pages = "867--875",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4′-methanol- bisbenzonitrile in vitro

AU - Jeong, Seongwook

AU - Woo, Margaret M.

AU - Flockhart, David A.

AU - Desta, Zeruesenay

PY - 2009/10

Y1 - 2009/10

N2 - Purpose: To determine the inhibitory potency of letrozole and its main human metabolite, 4,4′-methanol-bisbenzonitrile, on the activities of eight cytochrome P450 (CYP) enzymes. Methods: Letrozole and its metabolite were incubated with human liver microsomes (HLMs) (or expressed CYP isoforms) and NADPH in the absence (control) and presence of the test inhibitor. Results: Letrozole was a potent competitive inhibitor of CYP2A6 (Ki 4.6 ± 0.05 μM and 5.0 ± 2.4 μM in HLMs and CYP2A6, respectively) and a weak inhibitor of CYP2C19 (Ki 42.2 μM in HLMs and 33.3 μM in CYP2C19), while its metabolite showed moderate inhibition of CYP2C19 and CYP2B6. Letrozole or its metabolite had negligible effect on other CYPs. Conclusions: Based on the in vitro Ki values, letrozole is predicted to be a weak inhibitor of CYP2A6 in vivo. Letrozole and its major human metabolite show inhibitory activity towards other CYPs, but clinically relevant drug interactions seem less likely as the Ki values are above the therapeutic plasma concentrations of letrozole.

AB - Purpose: To determine the inhibitory potency of letrozole and its main human metabolite, 4,4′-methanol-bisbenzonitrile, on the activities of eight cytochrome P450 (CYP) enzymes. Methods: Letrozole and its metabolite were incubated with human liver microsomes (HLMs) (or expressed CYP isoforms) and NADPH in the absence (control) and presence of the test inhibitor. Results: Letrozole was a potent competitive inhibitor of CYP2A6 (Ki 4.6 ± 0.05 μM and 5.0 ± 2.4 μM in HLMs and CYP2A6, respectively) and a weak inhibitor of CYP2C19 (Ki 42.2 μM in HLMs and 33.3 μM in CYP2C19), while its metabolite showed moderate inhibition of CYP2C19 and CYP2B6. Letrozole or its metabolite had negligible effect on other CYPs. Conclusions: Based on the in vitro Ki values, letrozole is predicted to be a weak inhibitor of CYP2A6 in vivo. Letrozole and its major human metabolite show inhibitory activity towards other CYPs, but clinically relevant drug interactions seem less likely as the Ki values are above the therapeutic plasma concentrations of letrozole.

KW - Aromatase inhibitor

KW - Cytochrome P450

KW - Drug interaction

KW - Letrozole

KW - Metabolite

UR - http://www.scopus.com/inward/record.url?scp=69049103060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69049103060&partnerID=8YFLogxK

U2 - 10.1007/s00280-009-0935-7

DO - 10.1007/s00280-009-0935-7

M3 - Article

C2 - 19198839

AN - SCOPUS:69049103060

VL - 64

SP - 867

EP - 875

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 5

ER -